IVERIC bio, Inc. (ISEE)
Stock Price:
$5.99 USD
0.19 (3.28%)
Updated November 23, 4:00 PM EST - Market closed
After-hours: $5.96 -0.03 (-0.50%) Nov 23, 5:06 PM
Key Info
| Market Cap |
536.51M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-76.59M |
| Shares Out |
89.57M |
| EPS (ttm) |
-1.23 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
November 23 |
| Last Price |
$5.99 |
| Previous Close |
$5.80 |
| Change ($) |
0.19 |
| Change (%) |
3.28% |
| Day's Open |
5.90 |
| Day's Range |
5.76 - 6.11 |
| Day's Volume |
630,232 |
| 52-Week Range |
2.64 - 8.97 |
More Stats
| Market Cap |
536.51M |
| Enterprise Value |
305.52M |
| Earnings Date (est) |
Mar 2, 2021 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
89.57M |
| Float |
76.78M |
| EPS (basic) |
-1.26 |
| EPS (diluted) |
-1.23 |
| FCF / Share |
-0.61 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
3.38M |
| Short Ratio |
3.58 |
| Short % of Float |
4.40% |
| Beta |
1.66 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
2.36 |
| Revenue |
n/a |
| Operating Income |
-81.08M |
| Net Income |
-76.59M |
| Free Cash Flow |
-56.94M |
| Net Cash |
230.99M |
| Net Cash / Share |
2.58 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-30.40% |
| ROE |
-50.38% |
| ROIC |
-438.60% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (3)
| Buy |
3 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$13.00*
(117.03% upside)
Low
11.0
Current: $5.99
High
15.0
Target: 13.00
*Average 12-month price target from 3 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|
| Revenue | - | - | 210 | 50.91 | 51.51 | 41.26 | - | - | - |
| Revenue Growth | - | - | 312.46% | -1.16% | 24.83% | - | - | - | - |
| Gross Profit | - | - | 210 | 50.91 | 51.51 | 41.26 | - | - | - |
| Operating Income | -61.27 | -65.35 | 108 | -196 | -124 | -80.51 | -47.43 | -13.68 | -19.63 |
| Net Income | -58.86 | 63.09 | 114 | -193 | -106 | -117 | -51.15 | -14.56 | -18.63 |
| Shares Outstanding | 42.22 | 37.06 | 35.92 | 35.49 | 34.58 | 33.26 | 9.00 | 1.45 | 1.39 |
| Earnings Per Share | -1.39 | 1.70 | 3.17 | -5.45 | -3.06 | -3.51 | -6.34 | -14.89 | -18.27 |
| EPS Growth | - | -46.37% | - | - | - | - | - | - | - |
| Operating Cash Flow | -48.49 | -41.91 | -122 | -109 | -78.53 | 111 | -48.78 | -13.10 | -19.12 |
| Capital Expenditures | 0.15 | - | - | -0.57 | -2.61 | -1.66 | -0.01 | - | - |
| Free Cash Flow | -48.34 | -41.91 | -122 | -109 | -81.14 | 109 | -48.78 | -13.10 | -19.13 |
| Cash & Equivalents | 126 | 131 | 167 | 289 | 297 | 464 | 211 | 4.30 | 6.40 |
| Total Debt | 0.50 | - | - | - | - | - | - | 11.04 | - |
| Net Cash / Debt | 125 | 131 | 167 | 289 | 297 | 464 | 211 | -6.74 | 6.40 |
| Assets | 130 | 137 | 176 | 300 | 429 | 480 | 218 | 4.88 | 7.73 |
| Liabilities | 12.98 | 13.21 | 138 | 394 | 369 | 351 | 47.96 | 14.41 | 110 |
| Book Value | 117 | 124 | 38.04 | -94.62 | 59.95 | 129 | 170 | -123 | -102 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
IVERIC bio, Inc. |
| Country |
United States |
| Employees |
55 |
| CEO |
Glenn P. Sblendorio |
Stock Information
| Ticker Symbol |
ISEE |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: ISEE |
Description
IVERIC bio, a biopharmaceutical company, develops novel therapies to treat ophthalmic diseases with a focus on age-related and orphan retinal diseases. The company is developing Zimura, an inhibitor of complement factor C5, which is in Phase IIb clinical trials for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration. It is also developing High temperature requirement A serine peptidase 1 protein inhibitors for the treatment of GA and other age-related retinal diseases. The company has a license agreement with the University of Florida Research Foundation and the University of Pennsylvania for the development and commercialization of novel adeno-associated virus gene therapy product candidate for the treatment of rhodopsin-mediated autosomal dominant retinitis pigmentosa; and Best disease and other BEST1-related inherited retinal diseases. It also has a research agreement with the University of Massachusetts Medical School to develop gene therapy product candidates targeting Leber Congenital Amaurosis type 10 and autosomal recessive Stargardt disease; and IRDs associated with mutations in the USH2A gene. The company was formerly known as Ophthotech Corporation and changed its name to IVERIC bio, Inc. in April 2019. IVERIC bio, Inc. was founded in 2007 and is headquartered in New York, New York.